Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Regulation Review panel approves scheduling kratom as Schedule I; agency cites federal constraint and lab limits
Summary
The committee approved DCP's proposed regulation to classify kratom and related alkaloids as Schedule I, citing lack of FDA-approved medical use and limited state toxicology testing; members debated enforcement, lab capacity, and supports for affected users.
The Regulation Review Committee voted to accept the LCO recommendation approving proposed regulation 2026003 from the Department of Consumer Protection to classify kratom (and related alkaloids) as Schedule I under state rules.
Caitlin Anderson, chief of legal and regulatory affairs for the Department of Consumer Protection, told the committee the agency followed the statutory framework established for schedule classification and that the U.S. Food and Drug Administration has listed no approved medical use for kratom. "Because the FDA still has listed no approved medical use for kratom," Anderson said, the agency determined state rules required a Schedule I classification. Anderson also noted the regulation contains a reclassification provision so…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
